

Corrections


Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States



Value in Health. 2019; 22(2):168-176.

DOI of original article: [10.1016/j.jval.2018.08.011](https://doi.org/10.1016/j.jval.2018.08.011)

In the original published version of this article, Figure 1 on page 169 appeared incorrectly. The figure is shown correctly below:



EDSS indicates Kurtzke Expanded Disability Status Scale.

Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice



Value in Health. 2019; 22(1):38-44.

DOI of original article: <https://doi.org/10.1016/j.jval.2018.06.015>

At the request of the authors, the supplemental file containing STATA code was removed from the website.